JP2004504057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504057A5 JP2004504057A5 JP2002513918A JP2002513918A JP2004504057A5 JP 2004504057 A5 JP2004504057 A5 JP 2004504057A5 JP 2002513918 A JP2002513918 A JP 2002513918A JP 2002513918 A JP2002513918 A JP 2002513918A JP 2004504057 A5 JP2004504057 A5 JP 2004504057A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- hpv
- polypeptide
- encoding
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002157 polynucleotide Substances 0.000 description 24
- 108091033319 polynucleotide Proteins 0.000 description 20
- 102000040430 polynucleotide Human genes 0.000 description 20
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- 206010008263 Cervical dysplasia Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 5
- 206010059313 Anogenital warts Diseases 0.000 description 4
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 4
- 208000000907 Condylomata Acuminata Diseases 0.000 description 4
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 3
- 201000004201 anogenital venereal wart Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- -1 Amino Chemical group 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102220274708 rs1555866028 Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0017990.3A GB0017990D0 (en) | 2000-07-21 | 2000-07-21 | Papilloma virus sequences |
| GB0025802A GB0025802D0 (en) | 2000-10-20 | 2000-10-20 | Papilloma virus sequences |
| PCT/GB2001/003290 WO2002008435A1 (en) | 2000-07-21 | 2001-07-20 | Codon-optimized papilloma virus sequences |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004504057A JP2004504057A (ja) | 2004-02-12 |
| JP2004504057A5 true JP2004504057A5 (https=) | 2008-09-11 |
Family
ID=26244703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002513918A Pending JP2004504057A (ja) | 2000-07-21 | 2001-07-20 | コドン最適化されたパピローマウイルス配列 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1301614B1 (https=) |
| JP (1) | JP2004504057A (https=) |
| KR (1) | KR100874552B1 (https=) |
| CN (1) | CN1262665C (https=) |
| AT (1) | ATE346947T1 (https=) |
| AU (2) | AU7569501A (https=) |
| BR (1) | BR0112637A (https=) |
| CA (1) | CA2416488A1 (https=) |
| CY (1) | CY1106334T1 (https=) |
| CZ (1) | CZ2003180A3 (https=) |
| DE (1) | DE60124918T2 (https=) |
| DK (1) | DK1301614T3 (https=) |
| ES (1) | ES2277605T3 (https=) |
| HK (1) | HK1056195B (https=) |
| HU (1) | HUP0300745A3 (https=) |
| IL (1) | IL154009A0 (https=) |
| MX (1) | MXPA03000554A (https=) |
| NO (1) | NO20030219L (https=) |
| NZ (1) | NZ523683A (https=) |
| PL (1) | PL365385A1 (https=) |
| PT (1) | PT1301614E (https=) |
| WO (1) | WO2002008435A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| CA2457890A1 (en) * | 2001-08-23 | 2003-03-06 | Merck & Co., Inc. | Vaccine using papillomavirus e proteins delivered by viral vector |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US20040121465A1 (en) * | 2002-02-14 | 2004-06-24 | Novavax, Inc. | Optimization of gene sequences of virus-like particles for expression in insect cells |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| KR101080628B1 (ko) | 2003-03-24 | 2011-11-08 | 머크 샤프 앤드 돔 코포레이션 | 효모에서 ｈｐｖ 31 ｌ1의 최적 발현 |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| MY148656A (en) | 2004-03-24 | 2013-05-15 | Merck Sharp & Dohme | Optimized expression of hpv 52 l1 in yeast. |
| GB0617387D0 (en) * | 2006-09-04 | 2006-10-11 | Glaxo Group Ltd | Synthetic gene |
| WO2008133663A2 (en) * | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Codon modified immunogenic compositions and methods of use |
| GB0700914D0 (en) * | 2007-01-18 | 2007-02-28 | Animal Health Inst | Polynucleotides and uses thereof |
| CL2008000249A1 (es) | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| KR101621100B1 (ko) | 2007-03-30 | 2016-05-13 | 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 | 백신에 유용한 약독화 바이러스 |
| GB0710538D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Vaccine |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (fr) | 2015-07-21 | 2018-05-30 | Modernatx Inc | Vaccins contre une maladie infectieuse |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| CN108289913A (zh) | 2015-10-30 | 2018-07-17 | 儿童国家医疗中心 | 从未致敏t细胞群体产生hpv抗原特异性t细胞 |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464936A (en) * | 1990-12-21 | 1995-11-07 | Cetus Oncology Corporation | Compositions for identification of papillomavirus replication inhibitors |
| DE4123760C2 (de) * | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
| EE9900343A (et) * | 1997-02-07 | 2000-02-15 | Merck & Co., Inc. | Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon |
| SI1108035T1 (sl) * | 1998-09-04 | 2007-12-31 | Sanofi Pasteur Ltd | Zdravljenje raka materničnega vratu |
| EP1212358B1 (en) * | 1999-08-25 | 2004-12-15 | Merck & Co., Inc. | Synthetic papillomavirus genes optimized for expression in human cells |
-
2001
- 2001-07-20 HK HK03106686.3A patent/HK1056195B/en not_active IP Right Cessation
- 2001-07-20 CN CNB018161081A patent/CN1262665C/zh not_active Expired - Fee Related
- 2001-07-20 EP EP01953199A patent/EP1301614B1/en not_active Expired - Lifetime
- 2001-07-20 WO PCT/GB2001/003290 patent/WO2002008435A1/en not_active Ceased
- 2001-07-20 CA CA002416488A patent/CA2416488A1/en not_active Abandoned
- 2001-07-20 PT PT01953199T patent/PT1301614E/pt unknown
- 2001-07-20 KR KR1020037000847A patent/KR100874552B1/ko not_active Expired - Fee Related
- 2001-07-20 DE DE60124918T patent/DE60124918T2/de not_active Expired - Fee Related
- 2001-07-20 IL IL15400901A patent/IL154009A0/xx unknown
- 2001-07-20 ES ES01953199T patent/ES2277605T3/es not_active Expired - Lifetime
- 2001-07-20 HU HU0300745A patent/HUP0300745A3/hu unknown
- 2001-07-20 BR BR0112637-7A patent/BR0112637A/pt not_active Application Discontinuation
- 2001-07-20 DK DK01953199T patent/DK1301614T3/da active
- 2001-07-20 MX MXPA03000554A patent/MXPA03000554A/es active IP Right Grant
- 2001-07-20 AU AU7569501A patent/AU7569501A/xx active Pending
- 2001-07-20 AT AT01953199T patent/ATE346947T1/de not_active IP Right Cessation
- 2001-07-20 AU AU2001275695A patent/AU2001275695B9/en not_active Ceased
- 2001-07-20 JP JP2002513918A patent/JP2004504057A/ja active Pending
- 2001-07-20 PL PL01365385A patent/PL365385A1/xx unknown
- 2001-07-20 NZ NZ523683A patent/NZ523683A/en unknown
- 2001-07-20 CZ CZ2003180A patent/CZ2003180A3/cs unknown
-
2003
- 2003-01-16 NO NO20030219A patent/NO20030219L/no not_active Application Discontinuation
-
2007
- 2007-02-21 CY CY20071100246T patent/CY1106334T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504057A5 (https=) | ||
| JP2004512264A5 (https=) | ||
| US6066324A (en) | Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles | |
| KR101170654B1 (ko) | 효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현 | |
| KR101165278B1 (ko) | 효모에서의 ｈｐｖ 45 ｌ1의 최적화된 발현 | |
| JP2006501825A5 (https=) | ||
| AU725518B2 (en) | Virus-like particles useful as a vector delivering nucleic acid | |
| TWI731300B (zh) | 一種新型多價hpv 疫苗成份 | |
| JP2019068852A5 (https=) | ||
| KR101203403B1 (ko) | 효모에서 ｈｐｖ 52 ｌ1의 최적화된 발현 | |
| WO1999033868A2 (en) | Human papillomavirus vaccine | |
| CN101952320B (zh) | 具有免疫原性的物质 | |
| CN107249627B (zh) | 含有来自hpv e7蛋白质的多肽的乳酸菌的组合物 | |
| CN115960178A (zh) | 人乳头瘤病毒hpv59 l1蛋白的表达和类病毒样颗粒及其制备方法 | |
| CN103936840B (zh) | 重组的人乳头瘤病毒33型l1蛋白及其用途 | |
| KR102803235B1 (ko) | 타입 39 인유두종 바이러스 l1 단백질의 돌연변이체 | |
| US7314629B2 (en) | Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus | |
| JP4614765B2 (ja) | Ｌ２ペプチドを含むキメラ・ヒト・パピローマウイルス１６ｌ１タンパク質、それから調製したウイルス様粒子および該粒子の調製方法 | |
| EP2377879A1 (en) | N-terminal HPV E7 fusion proteins | |
| CN101181636A (zh) | 一种防治人乳头瘤病毒感染的复方疫苗组合物、复方疫苗阴道喷雾剂及其用途 | |
| RU2354701C2 (ru) | Полинуклеотидная последовательность, кодирующая полипептид вируса папилломы человека, ее применение, а также содержащие ее вектор и фармацевтическая композиция | |
| JP2006507797A5 (https=) | ||
| JP2002532434A5 (https=) | ||
| JP2006516386A5 (https=) | ||
| KR20200035963A (ko) | 인간 유두종 바이러스 타입 16의 l1 단백질의 변이체 |